Constructive is expanding what biology can do.
Constructive Bio is a biotechnology company built on a simple conviction: the molecules that matter most are often the ones that can’t yet be made.
Our Mission
We’ve rewritten the genetic code give cells access to new ncAA chemical building blocks — expanding the space of proteins that can be designed, engineered, and manufactured. Our platform moves from unexplored molecular territory to industrial-scale production, turning scientific possibility into manufacturable reality.
From next-generation medicines to advanced materials, Constructive shifts the question from “can we make this?” to “what should we make next?”
Our journey
2003
Foundational science
Pioneering work on genetic code expansion begins at MRC-LMB.
2019
Syn61 published
Publication of the world’s first organism with a fully synthetic, radically recoded genome.
2022
Seed funding and company launch
Constructive Bio established to commercialize breakthrough technology. $15 million
2024
Series A funding
Constructive raises Series A to advance platform development and expand partnerships. $58 million
2024
EIT Generative Biology Institute
Prof. Jason Chin appointed to lead the Ellison Institute of Technology’s new Generative Biology Institute.
2026
Pipeline advancement
Multiple programs advancing through development stages.
Our investors
We didn’t start Constructive to make incremental progress.
Biology runs on twenty amino acids. For billions of years, that was the limit — not of what scientists could imagine, but of what cells could build.
Constructive Bio exists to remove that constraint. By expanding the genetic code, we give researchers access to new chemical space: molecules with properties, functions, and therapeutic potential that natural biology cannot reach.
The result is not an incremental improvement in protein design and manufacture. It’s a way to scale proteins that were never before possible.
